Table 1 Baseline characteristics of the rheumatoid arthritis patients a
Baseline characteristics | Collection 1 (N= 438) | Collection 2 (N= 196) |
|---|---|---|
Age, mean ± SD years | 61.0 ± 12.04 | 56.3 ± 14.77 |
Age at diagnosis, mean ± SD years | 44.95 ± 13.03 | 42.99 ± 13.69 |
Females, n (%) | 365 (83.3) | 160 (81.6) |
Disease duration, mean ± SD years | 16.45 ± 8.34 | 12.93 ± 8.47 |
Rheumatoid factor–positive, n (%) | 340 (77.8) | 141 (71.94) |
Anti-CCP-positive, n (%) | 250 (69.6)b | 125 (73.1)c |
Smoking status, n (%) | ||
Ever-smoker | 51 (16.0)b | 20 (13.9)c |
Never-smoker | 267 (84.0)b | 124 (86.1)c |
Health status, mean ± SD | ||
DAS28 at baseline | 5.86 ± 1.12 | 5.36 ± 1.13 |
Treatment, n (%) | ||
Concurrent DMARDs | 252 (92.6)b | 159 (81.1) |
Previous biologic agents | 0 (0) | 14 (10.2)c |
Anti-TNF drugs, n (%) | ||
Infliximab | 245 (55.9) | 62 (31.6) |
Etanercept | 113 (25.8) | 21 (10.7) |
Adalimumab | 80 (18.3) | 113 (57.7) |
EULAR-defined response at 6 months, n (%) | ||
Responders | 337 (80.4) | 167 (85.2) |
Nonresponders | 82 (19.6) | 29 (14.8) |
EULAR-defined response at 12 months, n (%) | ||
Responders | 259 (82.5) | 118 (88.1) |
Nonresponders | 55 (17.5) | 16 (11.9) |